Rhabdomyosarcoma

Rhabdomyosarcoma is a type of cancer that starts in the soft tissues of the body, specifically the muscles. It's the most common soft tissue sarcoma in children. It can happen anywhere, but often affects the head, neck, arms, legs, or trunk. It's a serious cancer that can spread quickly.

Condition

What people with Rhabdomyosarcoma report

Every report comes from a Lived member, sent anonymously.

Have you tried Vincristine for Rhabdomyosarcoma?

NameHow it went

About Rhabdomyosarcoma

What It Is

Rhabdomyosarcoma is a cancer that forms in muscle tissue, from cells that would normally develop into the skeletal muscles that move the body. It is a type of soft tissue sarcoma and the most common soft tissue sarcoma in children. Despite its link to muscle, it can start almost anywhere, including around the eye, elsewhere in the head and neck, in the bladder, prostate, testicles or vagina, in the arms and legs, or in the chest or abdomen. Most cases are diagnosed in children and teenagers, and more than half occur in children younger than 10, though teens and adults can develop it too. It is rare: about 350 to 400 children are diagnosed each year in the United States. The main types behave differently. Embryonal rhabdomyosarcoma, the most common, usually affects young children and often starts in the head and neck or the urinary and genital organs. Alveolar rhabdomyosarcoma occurs at all ages, is found more often in the arms, legs or trunk, and is usually placed in a higher risk group. Spindle cell/sclerosing and pleomorphic types are less common.

Causes & Risk Factors

In most people with rhabdomyosarcoma, no cause is found. The cancer begins when changes in a cell's genes let it keep growing and dividing instead of maturing into muscle. In many alveolar tumors, pieces of two chromosomes have swapped places, joining a PAX gene to a gene called FOXO1 so that growth signals stay switched on. Whether a tumor carries this fusion (fusion-positive or fusion-negative) helps doctors judge how it is likely to behave: fusion-negative alveolar tumors act more like the embryonal type and generally have a better outlook. A small share of cases are linked to rare inherited conditions that raise the risk of several cancers, including Li-Fraumeni syndrome, DICER1 syndrome, neurofibromatosis type 1, Costello syndrome, Beckwith-Wiedemann syndrome and Noonan syndrome. Children who were unusually large at birth may have a somewhat higher risk of the embryonal type. Unlike many adult cancers, diet, weight, smoking and other lifestyle factors play no clear role, and there is nothing a child or parent could have done to prevent it. Because an inherited condition can matter for other relatives, a genetic counselor is often part of the care team.

How It's Diagnosed

Symptoms depend on where the tumor grows. The most common sign is a lump or swelling that keeps getting bigger or does not go away, which may or may not hurt. A tumor near the eye can make the eye bulge or turn inward. One in the nose or sinuses can cause nosebleeds, a blocked feeling or headaches. Tumors in the bladder, prostate or vagina can cause blood in the urine, vaginal bleeding, or trouble passing urine or stool. Most of these signs turn out to have more common explanations, such as an injury from play or sports. When a tumor is suspected, imaging such as MRI, CT and PET scans shows its size and position and whether it has spread. The diagnosis itself requires a biopsy, a tissue sample examined under a microscope, ideally by a pathologist experienced with this cancer, because the exact type shapes treatment. Laboratory tests on the sample look for gene changes such as the PAX-FOXO1 fusion. Other tests check for spread to lymph nodes, lungs, bones or bone marrow, and may include a bone marrow biopsy from the hip bones or a lumbar puncture (spinal tap) to examine the fluid around the brain and spinal cord. The results are combined into a risk group: low, intermediate or high. It reflects the tumor type and its gene changes, where it started, its size, how much could be removed by surgery, and whether it has spread to distant parts of the body. Some starting sites, such as around the eye, parts of the head and neck, the bile ducts, and the testicles or vagina, are called favorable because tumors there tend to respond better. The risk group decides how intensive treatment needs to be.

Treatment Options

Rhabdomyosarcoma is treated with chemotherapy combined with local treatment aimed at the tumor itself, meaning surgery, radiation therapy or both. Everyone with rhabdomyosarcoma receives chemotherapy, even when surgery appears to remove the whole tumor, because tiny amounts of cancer too small to see on scans are almost always present elsewhere and would otherwise be likely to grow back. Because the disease is rare and treatment is complex, care is best given by an experienced team at a children's cancer center for children and teens, or at a major cancer center for adults. Surgery removes the tumor when that can be done without major loss of function or changes in appearance. When it cannot, as is often the case near the eye, in other parts of the head and neck or in the pelvis, chemotherapy and radiation are used to shrink or control the tumor, sometimes making later surgery possible. Radiation is added when cancer remains after surgery or the tumor has higher-risk features. Techniques such as intensity-modulated radiation therapy and proton therapy shape the dose to spare nearby healthy tissue, which matters in a growing child. Chemotherapy usually combines vincristine, dactinomycin (also called actinomycin D) and cyclophosphamide, known as VAC. Some intermediate-risk plans alternate VAC with vincristine and irinotecan, while some low-risk tumors can be treated with fewer drugs. Treatment is typically weekly at first, then less often, and lasts from about six months to a year or more. Common effects include hair loss, nausea, mouth sores and low blood counts that raise the risk of infection; most fade after treatment ends. Two trade-offs are worth raising early. Cyclophosphamide, and radiation or surgery in the pelvis, can affect later fertility, so families should ask about fertility preservation before treatment starts. Vincristine can cause numbness, tingling or weakness in the hands and feet, which usually improves once treatment ends but does not always disappear. For high-risk disease, more intense chemotherapy has not proved better than VAC, and most specialists recommend joining a clinical trial testing new drug combinations or longer maintenance treatment. Clinical trials are also an option when the cancer returns.

What to Expect

Outlook depends heavily on the risk group. The figures below come from children and young adults treated in past clinical trials, so they are estimates rather than predictions for any one person, and treatment has continued to improve. Overall, about 70% of children are alive five years after diagnosis, and many are cured. In the low-risk group, five-year survival ranges from about 70% to over 90%. In the intermediate-risk group it is about 50% to 70%, and in the high-risk group, which includes cancer that has spread to distant parts of the body, it is about 20% to 30%. Children aged 1 to 9 tend to do better than infants, older children and adults, and rhabdomyosarcoma is often harder to treat in adults. Treatment usually spans many months of regular clinic visits, blood tests and repeat scans to check the response. Many experts encourage children to attend school as much as they can, and hospital social workers, school re-entry programs and families who have been through treatment can help with the practical and emotional load, including travel, time off work and costs. If the cancer returns, it is usually within the first few years after treatment, so follow-up exams and scans are frequent at first and spaced out over time. Because treatment is given to growing bodies, some effects can appear years later. These can include reduced growth of bone or soft tissue in an area that received radiation, nerve problems, fertility problems, effects on teeth, eyes or digestion, changes in learning or memory, and a small added risk of a second cancer. A survivorship care plan that records the treatment given and the checkups needed helps carry this follow-up into adult care.

When to Seek Help

See a doctor about a lump or swelling that keeps growing or has not gone away after a week or so, a bulging or turning eye, repeated nosebleeds or a persistently blocked nose, blood in the urine, unexplained vaginal bleeding, or new trouble passing urine or stool. These usually have other causes, but they deserve a timely check. During chemotherapy, call the cancer care team right away for a fever of 100.5°F (38°C) or higher, chills or other signs of infection, because infections when white blood cell counts are low can be life threatening and need urgent attention. Before treatment starts, ask for the team's after-hours number and its fever instructions, and check with them before giving fever-reducing medicine, which can hide a fever. After treatment, contact the team about new lumps, bone pain, a cough that does not go away or unexplained weight loss, which can signal that the cancer has spread or returned, and about numbness, weakness or other treatment effects that are not improving.

Questions to Ask Your Doctor

  1. 1.What type of rhabdomyosarcoma is this, does it carry a fusion gene, and which risk group does that place it in?
  2. 2.Which treatments are planned, in what order, and how might each affect function or appearance in this part of the body?
  3. 3.Is there a clinical trial that fits this situation, and how would it differ from standard treatment?
  4. 4.How could treatment affect future fertility, and what preservation options are available before it begins?
  5. 5.Which late effects should we watch for, and who will provide long-term follow-up care?

Last reviewed • Oct 2026

Educational content, not medical advice.